孙飘扬“借船出海”破局内卷 恒瑞医药创新药收入占比突破60%

Core Viewpoint - China's innovative pharmaceutical industry is entering a period of significant achievement, with 76 innovative drugs approved in 2025, over 80% of which are domestically produced, and total licensing transaction amounts exceeding $130 billion, setting a historical record [1] Group 1: Company Transformation - Heng Rui Medicine, originally a generics giant, has successfully transitioned to innovative drugs, with innovative drug revenue surpassing 60% of total revenue [1] - The company faced challenges starting in 2020 when the implementation of national drug procurement policies marked the end of high-profit margins for generics, leading to a decline in revenue and profit in 2021 and 2022 [2] - The management recognized the necessity for transformation due to shrinking profit margins in traditional generics and increasing competition, prompting a shift towards clinically differentiated innovations [2] Group 2: Leadership and Strategy - After stepping back for a year and a half, Sun Piaoyang returned to lead Heng Rui Medicine in July 2021, focusing on innovation and international expansion [3][4] - Upon his return, Sun made significant cuts to generics R&D projects, reallocating resources to innovative drug development, and expanded the R&D pipeline into diverse therapeutic areas [4] - The company adopted a differentiated R&D strategy, achieving notable successes in the ADC platform with over ten new ADC molecules approved for clinical trials [4] Group 3: Operational Changes - The company underwent a major restructuring, reducing the sales force by nearly 50% from 17,100 in 2020 to 8,910 by the end of 2024, while also streamlining its organizational structure [5][6] - The shift from a marketing-driven to a research-driven model was a key focus of the internal transformation [6] Group 4: Internationalization Efforts - In 2024, domestic revenue accounted for 86.81% of total revenue, while international revenue was only 2.56%, highlighting the need for greater international presence [6] - The "borrow a boat to go to sea" strategy was implemented to enhance international competitiveness, resulting in significant overseas licensing deals, including five overseas BD authorizations in 2023 totaling over $4 billion [6][7] - By 2025, Heng Rui had achieved 13 overseas licensing collaborations with a total transaction amount nearing $14 billion, further diversifying its international partnerships [7] Group 5: Financial Performance - In the first half of 2025, revenue from innovative drugs and licensing exceeded 60%, reaching 60.66%, while international revenue increased to 2.568 billion yuan, accounting for 16.29% of total revenue [7]